Share on

Middle East and Africa Plasma Protein Therapeutics Market Research Report – Segmented By Product Type, Application & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2022 to 2027)

Published: January, 2022
ID: 210
Pages: 134
Formats: report pdf report excel report power bi report ppt

MEA Plasma Protein Therapeutics Market Size (2022 to 2027)

The size of the Plasma Protein Therapeutics Market in the Middle East & Africa has been valued at USD 1197.23 Million in 2022 and held the most dominant share in the global market and is estimated to reach USD 1840.06 Million by the end of 2027, growing at a CAGR of 8.976% from 2022 to 2027.

Recent years have witnessed the increased usage of plasma proteins in medical applications. The advancements in technology have made the process for fractionating the protein from plasma more efficient and cost-saving and is a huge boost to the market. Reports suggest that half of the global blood donors are from high-income countries, constituting only 18% of the global population. Rising awareness among individuals regarding the significance of blood donations and government initiatives helped the market propel the market significantly.

Plasma is a protein-rich fluid that is responsible for blood clotting and providing immunity towards diseases. Isolation of these proteins from plasma can help provide medical therapies, which include immune deficiencies, autoimmune, neurological, and bleeding disorders. Plasma protein therapies help replace the deficient or missing proteins and help the individual lead a normal life. The therapies involve either the injection or infusion of biological medicines to treat life-threatening genetic and chronic diseases.

The introduction of new plasma-derived therapies in the market is the key driving force for the market, along with a host of other drivers that include increasing prevalence of life-threatening diseases involving neurological or immune systems like chronic inflammatory demyelinating polyneuropathy (CIPD), Idiopathic thrombocytopenic purpura (ITP) and other diseases such as Rabies, Hepatitis A&B, Tetanus and varicella. However, there are few hurdles the market must overcome to sustain in the future which including reimbursement issues, stringent regulatory policies, and complexities in manufacturing.

This research report on the Middle East and Africa Plasma Protein Therapeutics Market has been segmented and sub-segmented into the following categories:

By Type: 

  • Immunoglobulins
  • Albumin
  • Coagulation Factor
  • Alpha-1 Proteinase Inhibitor
  • Others

By Application: 

  • Hemophilia
  • Primary Immunodeficiency Disorder
  • Idiopathic Thrombocytopenic Purpura
  • Secondary Immunodeficiency
  • Others

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Major companies leading in the Middle East & Africa Plasma Protein Therapeutics Market profiled in this report are Grifols, CSL Behring, Baxter, Krdrion, China Biologics, Octapharma, Chendu Inst, and Shire Plc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample